AU2018393119B2 - Methods of treatment of hypertriglyceridemia - Google Patents

Methods of treatment of hypertriglyceridemia Download PDF

Info

Publication number
AU2018393119B2
AU2018393119B2 AU2018393119A AU2018393119A AU2018393119B2 AU 2018393119 B2 AU2018393119 B2 AU 2018393119B2 AU 2018393119 A AU2018393119 A AU 2018393119A AU 2018393119 A AU2018393119 A AU 2018393119A AU 2018393119 B2 AU2018393119 B2 AU 2018393119B2
Authority
AU
Australia
Prior art keywords
patient
week
pemafibrate
hdl
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018393119A
Other languages
English (en)
Other versions
AU2018393119A1 (en
Inventor
Gary Gordon
Ryu Oshima
Kazuhito SUEHIRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2018393119A1 publication Critical patent/AU2018393119A1/en
Application granted granted Critical
Publication of AU2018393119B2 publication Critical patent/AU2018393119B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018393119A 2017-12-21 2018-12-20 Methods of treatment of hypertriglyceridemia Active AU2018393119B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609048P 2017-12-21 2017-12-21
US62/609,048 2017-12-21
PCT/US2018/066976 WO2019126597A1 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Publications (2)

Publication Number Publication Date
AU2018393119A1 AU2018393119A1 (en) 2020-07-23
AU2018393119B2 true AU2018393119B2 (en) 2022-08-25

Family

ID=66995099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018393119A Active AU2018393119B2 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertriglyceridemia

Country Status (9)

Country Link
US (1) US20190224169A1 (https=)
EP (1) EP3727376A4 (https=)
JP (2) JP2021506907A (https=)
CN (1) CN111741753A (https=)
AU (1) AU2018393119B2 (https=)
CA (1) CA3085951C (https=)
MY (1) MY205171A (https=)
SG (1) SG11202005850VA (https=)
WO (1) WO2019126597A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4556006A4 (en) * 2022-07-15 2026-01-07 Kowa Co MEDICATION TO LOWER LDL CHOLESTEROL IN THE BLOOD
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
WO2025069226A1 (ja) * 2023-09-26 2025-04-03 興和株式会社 ペマフィブラートを含有する医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) * 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
ES2752039T3 (es) * 2012-09-27 2020-04-02 Kowa Co Agente terapéutico para la dislipidemia
EA201790091A1 (ru) * 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISHIBASHI SHUN; YAMASHITA SHIZUYA; ARAI HIDENORI; ARAKI EIICHI; YOKOTE KOUTARO; SUGANAMI HIDEKI; FRUCHART JEAN-CHARLES; KODAMA TAT: "Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 249, 26 February 2016 (2016-02-26), AMSTERDAM, NL , pages 36 - 43, XP029542969, ISSN: 0021-9150, DOI: 10.1016/j.atherosclerosis.2016.02.029 *

Also Published As

Publication number Publication date
US20190224169A1 (en) 2019-07-25
JP2023181451A (ja) 2023-12-21
MY205171A (en) 2024-10-04
AU2018393119A1 (en) 2020-07-23
CA3085951A1 (en) 2019-06-27
JP2021506907A (ja) 2021-02-22
WO2019126597A1 (en) 2019-06-27
EP3727376A4 (en) 2021-07-21
SG11202005850VA (en) 2020-07-29
EP3727376A1 (en) 2020-10-28
CN111741753A (zh) 2020-10-02
CA3085951C (en) 2022-10-11

Similar Documents

Publication Publication Date Title
US11446282B2 (en) Methods of treating mixed dyslipidemia and hypertriglycertdemia
Cariou et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
US10869859B2 (en) Methods of preventing the occurrence of cardiovascular events
Xie et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study
Kastelein et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
Nolan Metabolic complications associated with HIV protease inhibitor therapy
Pu et al. Protective effects of sulforaphane on cognitive impairments and AD-like lesions in diabetic mice are associated with the upregulation of Nrf2 transcription activity
JP2023181451A (ja) 高トリグリセライド血症の治療方法
Mohiuddin et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study
Song et al. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation
Friedland et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists
JP2018536710A (ja) 混合型脂質異常症の治療
Bays et al. Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial
Baszczuk et al. The impact of supplementation with folic acid on homocysteine concentration and selected lipoprotein parameters in patients with primary hypertension
Chen et al. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study
Wei et al. Betel nut chewing associated with increased risk of arterial stiffness
TWI741379B (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
Stefanutti et al. Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol
Ballantyne et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study
Chen et al. Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic–reperfusion injury by targeting the NOX2/AMPK pathway
Zeni Klafke et al. Biomarkers of subclinical atherosclerosis and natural products as complementary alternative medicine
Aguilar-Salinas et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study
Hobbs Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control
US20230092776A1 (en) Methods of treating mixed dyslipidemia and hypertriglyceridemia
Roy et al. Significant reduction of elevated triglycerides and liver fibrosis in diabetic dyslipidemia with saroglitazar: A case report

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS OF TREATMENT OF HYPERTRIGLYCERIDEMIA

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ OSHIMA, RYU; SUEHIRA, KAZUHITO AND GORDON, GARY

FGA Letters patent sealed or granted (standard patent)